An Alternative Dendritic Cell-Induced Murine Model of Asthma Exhibiting a Robust Th2/Th17-Skewed Response by 신성재 et al.
537https://e-aair.org
ABSTRACT
Purpose: Simple and reliable animal models of human diseases contribute to the 
understanding of disease pathogenesis as well as the development of therapeutic interventions. 
Although several murine models to mimic human asthma have been established, most of them 
require anesthesia, resulting in variability among test individuals, and do not mimic asthmatic 
responses accompanied by T-helper (Th) 17 and neutrophils. As dendritic cells (DCs) are known 
to play an important role in initiating and maintaining asthmatic inflammation, we developed 
an asthma model via adoptive transfer of allergen-loaded DCs.
Methods: Ovalbumin (OVA)-loaded bone marrow-derived DCs (BMDCs) (OVA-BMDCs) were 
injected intravenously 3 times into non-anesthetized C57BL/6 mice after intraperitoneal 
OVA-sensitization.
Results: OVA-BMDC-transferred mice developed severe asthmatic immune responses when 
compared with mice receiving conventional OVA challenge intranasally. Notably, remarkable 
increases in systemic immunoglobulin (Ig) E and IgG1 responses, Th2/Th17-associated cytokines 
(interleukin [IL]-5, IL-13 and IL-17), Th2/Th17-skewed T-cell responses, and cellular components, 
including eosinophils, neutrophils, and goblet cells, were observed in the lungs of OVA-BMDC-
transferred mice. Moreover, the asthmatic immune responses and severity of inflammation 
were correlated with the number of OVA-BMDCs transferred, indicating that the disease severity 
and asthma type may be adjusted according to the experimental purpose by this method. 
Furthermore, this model exhibited less variation among the test individuals than the conventional 
model. In addition, this DCs-based asthma model was partially resistant to steroid treatment.
Conclusions: A reliable murine model of asthma by intravenous (i.v.) transfer of OVA-
BMDCs was successfully established without anesthesia. This model more accurately 
reflects heterogeneous human asthma, exhibiting a robust Th2/Th17-skewed response and 
eosinophilic/neutrophilic infiltration with good reproducibility and low variation among 
individuals. This model will be useful for understanding the pathogenesis of asthma and 
would serve as an alternative tool for immunological studies on the function of DCs, T-cell 
responses and new drugs.
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INTRODUCTION
A heterogeneous lung inflammation in asthma is characterized by airway remodeling, airway 
hyperresponsiveness (AHR), and mucus hypersecretion, involving various immune cells and 
mediators.1 Asthma has long been regarded as a T-helper (Th) 2-dependent, immunoglobulin 
(Ig) E-mediated disease. However, emerging evidence suggests that asthma is a complex 
disease displaying various endotypes: eosinophilic, neutrophilic, mixed eosinophilic/
neutrophilic, and paucigranulocytic2,3 or Th2-predominant, Th2/Th17-predominant, and 
Th2/Th17-low asthma.4,5
Approximately 358 million people suffer from asthma worldwide and its incidence continues to 
increase.6 Current guidelines for asthma management rely on various agents, including new and 
emerging drugs; however, the medical need is still unmet. Asthma is a consequence of complex 
host-environment interactions and has many phenotypic features involving various immune 
responses.7 Thus, there is a continuous research effort for better targeted and personalized 
therapy as well as a deeper understanding of the complex pathophysiology of this disease.8
A variety of animal models of asthma have been established not only for understanding the 
pathophysiology, but also for evaluating the efficacy and safety of new therapeutic agents.9 Mice 
are the most widely used model animals because of the availability of comprehensive genetic 
information and transgenic, congenic, and knockout animals, which allow examining the 
effect of a specific gene in disease onset and development. Other advantages are that numerous 
mouse inbred strains are available and methods for measuring cytokines, growth factors, 
and cell-surface molecules are well established.9,10 Mice do not naturally develop human-like 
asthma; thus, to investigate the underlying processes, an asthmatic-like reaction, mainly 
representing Th2-type response-mediated disease, has been induced using various allergens.10
There are various sensitization and challenge protocols to induce experimental asthma in 
mice. Chicken egg ovalbumin (OVA) is the most frequently used allergen to induce a Th2-
skewed response because of its high purity and immunodominant epitopes. Moreover, using 
OVA enables immunological application, for example, in transgenic mice bearing T cells 
expressing OVA-specific T-cell receptors.11 Generally, mice are first systemically immunized 
with OVA, usually by intraperitoneal (i.p.) injection, followed by repetitive inhalation of 
OVA by intranasal (i.n.),12-14 intratracheal (i.t.),15-17 or nebulized formulation (aerosol),13,18,19 
resulting in a robust influx of inflammatory cells in the lungs and elevation of IgE levels. 
However, sensitizing mice with OVA alone via inhalation induces immune tolerance rather 
than overt asthma-like airway responses.20 Therefore, a refined murine model that more 
accurately and strongly induces asthma-related immune responses is needed.
Moreover, the conventional methods for establishing murine asthma models have several 
limitations. For example, mice have to be anesthetized for repetitive allergen inhalation via 
the i.n. route. Repeated anesthesia for consecutive days can be stressful for the mice as well 
as the researchers, and anesthesia itself is an artificially controlled condition and can result 
in variable outcomes. Further, the amount of inhaled allergen can differ among individuals, 
causing phenotypic variation even within an experimental group. Moreover, the conventional 
models do not reflect heterogeneous human asthma because of lack of non-allergic asthmatic 
responses accompanied by Th17 and neutrophils.21
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Dendritic cells (DCs) are the most specialized antigen-presenting cells that play a critical 
role in initiating and directing asthma.7,22 Once activated, mature DCs migrate to local 
lymph nodes where they interact with naïve T cells to drive the differentiation of T cells 
into Th1, Th2, Th9, Th17, or regulatory T cells.22 DCs are important targets for studying 
the pathophysiology and treatment of asthma because they play a crucial role in striking a 
balance between immune activation and immune tolerance.23-25
To address the above issues, in the present study, we aimed to develop a reliable murine 
model of asthma through direct i.v. administration of OVA-loaded DCs into the mice, thereby 
circumventing the need for anesthesia. This method induces more severe inflammation 
than conventional methods and allows for high productivity. In addition, we examined the 
immunologic effect of direct transfer of DCs and checked the variability between individuals.
MATERIALS AND METHODS
Mice
Female C57BL/6J mice, 4-5 weeks of age, were purchased from Japan SLC, Inc. (Shizuoka, 
Japan) and were maintained under specific pathogen-free conditions. The use of animals in this 
study was approved by the Ethics Committee and Institutional Animal Care and Use Committee 
of Yonsei University Health System (2017-0342), and the study was conducted according to the 
International Association of Veterinary Editors guidelines on animal experiments.
Murine models of asthma
To establish a conventional asthma model, a previously published protocol was used,12 with 
slight modification. Mice were sensitized on days 0 and 14 via i.p. injection of 50 μg OVA 
(grade V; Sigma-Aldrich, St. Louis, MO, USA) emulsified in 1.32 mg alum gel (Sigma-Aldrich) 
in a total volume of 200 μL. Phosphate-buffered saline (PBS)-treated mice served as the 
negative control group. Anesthetized mice were challenged i.n. with 150 μg of OVA in 30 μL 
of PBS for 5 consecutive days starting from day 21. Mice were analyzed 24 hours after the last 
challenge (Fig. 1A).
The murine model of asthma was established via transfer of OVA-loaded DCs. On days 0 and 
14, i.p., OVA sensitization was done as per the conventional method. On days 21, 23 and 25, 
1 × 107 OVA (500 μg)-loaded bone marrow-derived DCs (BMDCs) (OVA-BMDCs) in a total 
volume of 200 μL were injected i.v. (via the tail vein) into non-anesthetized mice. Mice were 
analyzed 24 hours after the last transfer (Fig. 1B). In addition, i.v. OVA-BMDC transfer without 
i.p. sensitization was used (Fig. 1C).
In some experiments, dexamethasone (10 mg/kg; Sigma-Aldrich) or vehicle (0.25% PEG400, 
0.25% Tween20 in dH2O) was administered to the mice by oral gavage 2 hours prior to i.n. 
challenge or i.v. transfer for 5 consecutive days starting from day 21.
Generation of OVA-BMDCs
BMDCs were generated from BM using a conventional method.26 Whole BM cells isolated 
from C57BL/6J mice were cultured in RPMI 1640 medium supplemented with 100 units/mL 
of penicillin/streptomycin (Lonza, Basel, Switzerland), 10% fetal bovine serum (Lonza), 50 
μM mercaptoethanol (Lonza), and 20 ng/mL granulocyte-macrophage colony-stimulating 
factor (GM-CSF) plus 5 ng/mL interleukin (IL)-4 at 37°C in the presence of 5% CO2. On days 3 
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and 6, the medium was refreshed. On day 8, BMDCs were harvested and incubated in 24-well 
multiwell plates (1 × 106 cells/well) in the presence of OVA protein (500 μg/mL) for 24 hours. 
On day 9, OVA-BMDCs were harvested.
Histological assessment of lung tissue
Lung tissue was fixed in 10% neutral buffered formalin and embedded in paraffin. Paraffin-
embedded tissue sections were stained with hematoxylin and eosin (H&E) or periodic acid-Schiff 
(PAS) solution. Lung inflammation and goblet cell hyperplasia were graded using a previously 
reported semiquantitative scoring system.27 To grade inflammatory cell infiltration, peribronchial 
cell counts were determined on the basis of a 5-point grading system as follows: 0, normal; 1, 
few cells; 2, a ring of inflammatory cells one cell layer deep; 3, a ring of inflammatory cells of 2–4 
cells deep; and 4, a ring of inflammatory cells of more than 4 cells deep. Eight fields were counted 
for each section, and the mean score from 5–7 mice per group was calculated. To quantify airway 
goblet cells, the following 5-point grading system was used: 0, < 0.5% PAS-positive cells; 1, < 25%; 
2, 25%–50%; 3, 50%–75%; and 4, > 75%. Eight fields were counted for each section, and the mean 
area or mean score from 5–7 mice per group was calculated. Analyses were conducted in a blinded 
manner, and slides were presented in random order for each examination.
Analysis of AHR
AHR was measured by whole-body plethysmography (Buxco, Wilmington, NC, USA) with a 
technical support from the Korea Mouse Phenotyping Center (Seoul, Korea) as previously 
described.28 AHR was represented as enhanced pause (Penh) in response to increasing 
concentrations of methacholine (6.25–50 mg/mL). Penh values measured during this period 
were averaged and expressed as absolute Penh values.
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Fig. 1. Experimental protocol for the development of asthma in mice. (A) Conventional OVA-induced asthma 
model by i.p. OVA sensitization and i.n. OVA challenge under anesthesia. (B) Asthma model established by i.v. 
transfer of DCs. After i.p. OVA sensitization, OVA-BMDCs were injected i.v. instead of i.n. (C) I.v. transfer of OVA-
BMDCs alone without i.p. OVA sensitization was included in some experiments. There was no need for anesthesia 
for i.v. transfer of DCs. For some experiments, mice of asthma group were treated with vehicle or dexamethasone 
during the period of i.n. OVA challenge or i.v. transfer of DCs. 
OVA, ovalbumin; BMDC, bone marrow-derived dendritic cell; OVA-BMDC, ovalbumin-loaded bone marrow-
derived dendritic cell; DC, dendritic cell; i.p., intraperitoneal; i.n., intranasal; i.v., intravenous; Dexa, 
dexamethasone; Veh, vehicle.
Flow-cytometric analysis and intracellular cytokine staining
To analyze myeloid cells, single-cell suspensions were blocked with Fc Block (anti-CD16/32;  
eBioscience, San Diego, CA, USA) at 4°C for 15 minutes and then stained with fluorochrome-
conjugated anti-CD3e, anti-CD11b, anti-CD103, anti-F4/80, anti-MHCII (eBioscience), 
anti-CD4, anti-Ly6G, anti-Siglec-F (BD Biosciences, San Jose, CA, USA), and anti-CD11c, 
anti-CD19, and anti-CD64 (BioLegend, San Diego, CA, USA) antibodies at 4°C for 30 
minutes. Cells stained with appropriate isotype-matched antibodies were used as negative 
controls. Cells were fixed using an IC fixation buffer (eBioscience) in accordance with the 
manufacturer's instructions. The stained cells were analyzed using a BD LSR II Fortessa 
flow cytometer (BD Biosciences) and FlowJo software (Tree Star, Inc., Ashland, OR, 
USA). T-cell transcription factors and Treg marker expression were analyzed by staining 
with fluorochrome-conjugated anti-CD3e (eBioscience), anti-CD4, and anti-CD25 (BD 
Biosciences) antibodies, followed by permeabilization with a fixation/permeabilization kit 
(eBioscience) in accordance with the manufacturer's instructions and intracellular staining 
with anti-T-bet, anti-GATA3, anti-RORγt and anti-Foxp3 (eBioscience) antibodies. To 
restimulate cells with the antigen, lung cells (1 × 106 cells/well) and spleen cells (2 × 106 cells/
well) were restimulated with OVA protein (10 μg/mL) at 37°C. Intracellular cytokines of CD4+ 
T cells were quantified after 2 hours of incubation with the antigen, 4 hours of incubation 
with GolgiStop (eBioscience), and permeabilization, followed by intracellular staining 
with fluorochrome-conjugated anti-interferon (IFN)-γ, anti-IL-4, anti-IL-5 and anti-IL-17 
(eBioscience) antibodies. To determine cytokine levels by an ex vivo recall assay, supernatants 
were harvested after 72 hours of incubation with the antigen, and cytokine production was 
analyzed via enzyme-linked immunosorbent assay (ELISA).
ELISA of antigen-specific antibodies
Serum antigen-specific antibodies were quantified by sandwich ELISA as previously 
described,29 with minor modifications. Plates were coated with OVA (1 mg/mL). Serum 
dilutions were 1:50 for OVA-specific IgE and 1:10,000 for OVA-specific IgG1. Biotinylated 
anti-mouse IgE (clone: R35-118) and anti-mouse IgG1 (clone: A85-1) were used, followed by 
incubation with horseradish peroxidase-conjugated streptavidin.
Statistical analysis
All data are representative of at least 3 independent experiments with consistent results, 
with 5–7 mice per group in each experiment. Means were compared using 1-way analysis of 
variance followed by Tukey's multiple comparison test when data were normally distributed 
using Prism 5 (version 5; GraphPad Software, San Diego, CA, USA). To assess normality, the 
Shapiro-Wilk test was used. A P value < 0.05 was considered significant.
RESULTS
Mice receiving i.v. OVA-BMDCs exhibit more severe lung inflammation than 
conventional asthma model mice
To evaluate the asthma phenotype, we first analyzed lung histopathology. H&E staining 
revealed increased peribronchial, perivascular, and parenchymal infiltration of inflammatory 
cells in conventional asthma model mice compared to negative control mice. I.v. OVA-BMDC-
transferred asthma model mice developed stronger inflammatory cell infiltration than did 
conventional model mice. Interestingly, mice receiving i.v. OVA-BMDCs alone, without i.p. 
OVA challenge, also showed inflammatory cell infiltration (Fig. 2A).
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PAS staining revealed that the goblet cell population was expanded in conventional asthma 
model mice compared to negative control mice. Strikingly, this population was the most 
increased in i.v. OVA-BMDC-transferred asthma model mice (Fig. 2B).
These microscopic findings were confirmed by semiquantitative scoring of the inflammatory 
cell infiltration and PAS-positive cells. Notably, there was less variation in inflammatory 
scores and PAS scores among individuals in the i.v. OVA-BMDC-transferred than in the 
conventional model group (mean ± standard deviation: 2.97 ± 0.30 vs. 2.22 ± 0.80 and 3.32 ± 
0.41 vs. 1.79 ± 0.65, respectively; Fig. 2C).
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Fig. 2. Assessment of lung histology in the various asthma models. (A) Representative H&E-stained lung tissue sections (original magnification: 100×, magnified 
image of the 10× image in the left upper quadrant, scale bar: 100 μm) and (B) Representative PAS-stained sections (original magnification: 200×, scale bar: 
50 μm) in control mice (i.p. PBS and i.n. PBS-challenged), conventional asthma model mice (i.p. OVA-sensitized and i.n. OVA-challenged), alternative asthma 
model mice (i.p. OVA-sensitized and i.v. injected with OVA-BMDCs [1 × 107 cells]), and mice injected i.v. with OVA-BMDCs (1 × 107 cells) alone, without i.p. OVA 
sensitization. (C) Lung inflammation and PAS-positive cell score. Figures comprise histological examination data representative of 5 to 7 mice per group. All data 
are representative of 3 independent experiments with similar results. Data are expressed as the mean ± standard deviation. Means were compared using 1-way 
analysis of variance followed by Tukey's multiple comparison test when data were normally distributed. 
PBS, phosphate-buffered saline; OVA, ovalbumin; BMDC, bone marrow-derived dendritic cell; OVA-BMDC, ovalbumin-loaded bone marrow-derived dendritic 
cell; i.p., intraperitoneal; i.n., intranasal; i.v., intravenous; H&E, hematoxylin and eosin; PAS, periodic acid–Schiff; NS, not significant. 
*P < 0.01, †P < 0.001.
In addition, we checked the phenotype of i.p. PBS-sensitized and i.v. PBS-BMDCs-transferred 
mice, because they are an ideal negative control group for the i.p. OVA-sensitized and i.v. 
OVA-BMDC-transferred asthma group. In i.p. PBS-sensitized and i.v. PBS-BMDCs-transferred 
mice, the infiltration of inflammatory cells and goblet cells (Supplementary Fig. S1A-C) and 
OVA-specific IgE and IgG1 (Supplementary Fig. S1D) was not increased compared to the 
asthma groups; this was similar to the results in i.p. PBS-sensitized and i.n. PBS-challenged 
mice. Thus, in subsequent experiments, we used i.p. PBS-sensitized and i.n. PBS-challenged 
mice as negative control group.
The severity of asthma correlates with the number of OVA-BMDCs transferred
To elucidate the effect of the number of BMDCs injected in i.v. OVA-BMDC-transferred 
asthma model mice, we investigated lung histology in mice injected with increasing numbers 
of OVA-BMDCs (2 × 106, 5 × 106 and 1 × 107 cells). At a dose of 2 × 106 cells, inflammatory 
cell infiltration was comparable or slightly higher than that in conventional asthma model 
mice. The inflammation increased gradually as the cell number increased (Supplementary 
Fig. S2A). Goblet cell infiltration at 2 × 106 OVA-BMDCs reached a level similar to that 
in conventional model mice and then increased with increasing cell number, reaching 
a maximum at 1 × 107 cells (Supplementary Fig. S2B). These findings were validated by 
inflammatory cell infiltration and PAS score findings. As shown in Supplementary Fig. S2C, 
i.p. OVA challenge combined with i.v. 1 × 107 OVA-BMDCs induced the most severe lung 
inflammation and goblet cell infiltration.
Next, we aimed to find the appropriate concentration of OVA for priming BMDCs. CD11c and 
MHCII double-positive DCs were examined. BMDCs were stimulated with increasing doses 
of OVA (0, 10, 100, and 500 μg/mL) (Supplementary Fig. S3A and B). The expression of CD80 
and CD86, co-stimulatory molecules of DCs, increased with increasing OVA concentration. 
Expression of OX40L, a Th2 inducer, also increased with increasing OVA concentration 
(Supplementary Fig. S3C). Based on the data, 500 μg/mL OVA for priming BMDCs was 
considered effective for inducing asthma in the present study.
Mice receiving i.v. OVA-BMDCs present stronger systemic and local allergy-
associated immune responses than conventional asthma model mice
AHR determined by methacholine exposure, a key feature of allergic asthma, was increased 
in conventional asthma model mice than in negative control mice. I.v. OVA-BMDC-
transferred asthma model mice also enhanced AHR when accompanied by i.p. OVA 
sensitization, comparable to conventional asthma model mice (Fig. 3A).
The serum levels of OVA-specific IgE and IgG1 were elevated in conventional asthma model 
mice when compared to negative control mice, but were more strongly increased in i.v. 
OVA-BMDC-transferred asthma model mice. Particularly, a more than 2-fold increase in 
OVA-specific IgE was seen in the i.v. OVA-BMDC-transferred asthma model mice, with less 
variation among individuals than in the conventional asthma model mice (2.04 ± 0.28 vs. 
0.77 ± 0.60) (Fig. 3B).
Next, we examined the population of eosinophils and neutrophils in bronchoalveolar lavage 
(BAL) fluid and the lungs (Fig. 3C). In BAL fluid, eosinophil and neutrophil counts were 
significantly higher in i.v. OVA-BMDC-transferred asthma model mice, independent of prior 
i.p. OVA sensitization, than in conventional asthma model mice. In the lungs, eosinophil 
and neutrophil infiltration was also higher in the i.v. OVA-BMDC-transferred than in the 
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conventional asthma model mice. Interestingly, i.v. transfer of OVA-BMDCs alone, without i.p. 
OVA sensitization, was sufficient to induce eosinophil and neutrophil recruitment (Fig. 3D).
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Fig. 3. Evaluation of AHR, serum OVA-specific Ig, and myeloid cells. (A) AHR represented as Penh in response to methacholine. (B) Serum OVA-specific Ig 
measured by ELISA. (C) Gating strategy for the examination of myeloid cells in BAL fluid and lungs. (D) Populations of eosinophils and neutrophils in BAL 
fluid and lung. All data are representative of 3 independent experiments with similar results. Data are expressed as means ± standard deviation. Means were 
compared using 1-way analysis of variance followed by Tukey's multiple comparison test when data were normally distributed. 
AHR, airway hyperresponsiveness; PBS, phosphate-buffered saline; OVA, ovalbumin; BMDC, bone marrow-derived dendritic cell; OVA-BMDC, ovalbumin-loaded 
bone marrow-derived dendritic cell; i.p., intraperitoneal; i.n., intranasal; i.v., intravenous; Mch, methacholine; Ig, immunoglobulin; BAL, bronchoalveolar lavage; 
ELISA, enzyme-linked immunosorbent assay; NS, not significant; OD, optical density. 
*P < 0.05, †P < 0.01, ‡P < 0.001.
Together, these results suggested that systemic (serum IgE and IgG1) as well as local 
(eosinophils and neutrophils in the lungs and bronchus) immune responses were 
robustly induced in i.v. OVA-BMDC-transferred asthma model mice. In addition, i.p. OVA 
sensitization is required for inducing asthma-related systemic immune responses.
Mice receiving i.v. OVA-BMDCs display an aggravated Th2/Th17-mediated 
immune response
To examine the T-cell immune response, we measured cytokine expression in OVA-
restimulated lungs, spleen and mediastinal lymph node (MLN) cells. The expression of the 
Th2 cytokines IL-5 and IL-13 in the lungs was the highest in i.v. OVA-BMDC-transferred 
asthma model mice, followed by mice receiving i.v. OVA-BMDCs alone (Fig. 4A). A similar 
expression pattern was noted in the spleen and MLN cells (Supplementary Fig. S4A and B). 
Meanwhile, the levels of IFN-γ and IL-17 in the lungs, spleen, and MLN cells were elevated 
in the i.v. OVA-BMDC-transferred asthma model mice, but were the highest in the mice 
receiving i.v. OVA-BMDCs alone; the exception being IL-17 in spleen cells.
Next, we checked the expression of intracellular cytokines in CD4+ T cells of the lung (Fig. 4B). 
The populations of IL-4+ CD4+ and IL-5+ CD4+ T cells were elevated in conventional asthma 
model mice and in mice receiving i.v. OVA-BMDCs alone, but were more strongly increased in 
i.v. OVA-BMDC-transferred asthma model mice. The population of IL-17+ CD4+ T cells was the 
largest in i.v. OVA-BMDC-transferred asthma model mice, whereas the population of IFN-γ+ 
CD4+ T cells was the largest in mice receiving i.v. OVA-BMDCs alone (Fig. 4C).
To confirm T-cell polarization, we examined T-cell transcription factors of the lung. The 
relative mean fluorescence intensity (MFI) was measured in each group compared to that in 
negative control mice. The levels of T-bet and GATA3 were comparable between the negative 
control and conventional asthma model mice. However, in i.v. OVA-BMDC-transferred 
asthma model mice, the level of T-bet was elevated by more than 2-fold, whereas a more than 
3-fold increase was observed in the level of GATA3, suggesting that the Th2 immune response 
was robustly induced especially in these mice (Fig. 4D).
Collectively, these data suggested that i.v. transfer of OVA-BMDCs induced a stronger 
T-cell immune response than the conventional method. Th1, Th2 and Th17 levels were all 
augmented, but i.p. OVA sensitization before i.v. injection of OVA-BMDCs induced a stronger 
Th2/Th17 immune response, representing heterogeneous human asthma.
Mice receiving i.v. OVA-BMDCs are partially resistant to steroid treatment
In addition, we evaluated the response to therapeutic application of dexamethasone, since 
resistance to steroid treatment is another major issue in severe human asthma. In conventional 
asthma model mice, infiltration of inflammatory cells (Fig. 5A) and hyperplasia of goblet 
cell (Fig. 5B) were significantly decreased after dexamethasone administration. However, 
i.v. OVA-BMDC-transferred asthma model mice showed partially decreased populations of 
inflammatory (Fig. 5A) and goblet cells (Fig. 5B) after the same dexamethasone treatment.
The serum level of OVA-specific IgE was also decreased in conventional asthma model mice after 
dexamethasone administration, whereas it was partially attenuated in i.v. OVA-BMDC-transferred 
asthma model mice (Fig. 5C). Moreover, dexamethasone treatment significantly reduced 
eosinophil population (Fig. 5D) and IL-13 expression in the lung (Fig. 5E) of the conventional 
asthma model, whereas it had limited effect in i.v. OVA-BMDC-transferred asthma model mice.
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* i.p. PBS + i.n. PBS
i.p. OVA + i.n. OVA
i.p. OVA + i.v. OVA-BMDCs
i.v. OVA-BMDCs alone






























Fig. 4. Cytokine profiles and analysis of T cell transcription factors in CD4+ T cells of lung. (A) Cytokines were measured by ex-vivo recall assays with OVA protein (10 
μg/mL) in isolated lung cells. (B) Gating strategy for the examination of intracellular cytokines and transcription factors of CD4+ T cells. (C) Intracellular levels of IL-4, 
IL-5, IL-17 and IFN-γ as measured by flow cytometry after stimulation with OVA (10 μg/mL) for 2 hours with GolgiStop. (D) T-cell transcription factors showing relative 
MFI of T-bet and GATA3. All data are representative of 3 independent experiments with similar results. Data are expressed as the mean ± standard deviation. Means 
were compared using one-way analysis of variance followed by Tukey's multiple comparison test when data were normally distributed. 
PBS, phosphate-buffered saline; OVA, ovalbumin; BMDC, bone marrow-derived dendritic cell; OVA-BMDC, ovalbumin-loaded bone marrow-derived dendritic 
cell; i.p., intraperitoneal; i.n., intranasal; i.v., intravenous; IL, interleukin; IFN, interferon; MFI, mean fluorescence intensity; NS, not significant. 
*P < 0.05, †P < 0.01, ‡P < 0.001.
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i.p. PBS + i.n. PBS
i.p. OVA + i.n. OVA + p.o. Veh
i.p. OVA + i.n. OVA + p.o. Dexa
i.p. OVA + i.v. OVA-BMDCs + p.o. Veh
i.p. OVA + i.v. OVA-BMDCs + p.o. Dexa
Fig. 5. Effect of dexamethasone administration on lung histology and immune responses. (A) Representative H&E-stained lung tissue sections (original 
magnification: 100×, magnified image of the 10× image in the left upper quadrant, scale bar: 100 μm) with lung inflammation score and (B) Representative 
PAS-stained sections (original magnification: 200×, scale bar: 50 μm) with PAS-positive cell score in control i.p. PBS and i.n. PBS-challenged mice (PBS/PBS), 
conventional i.p. OVA-sensitized and i.n. OVA-challenged asthma model mice (OVA/OVA), new i.p. OVA-sensitized and i.v. transfer of OVA-BMDCs asthma model 
mice (OVA/OVA-BMDCs). Asthma mice were administered dexamethasone (10 mg/kg) or vehicle. Figures show the histological examination data representative 
of 5 to 7 mice per group. (C) Serum OVA-specific IgE measured by ELISA. (D) Population of eosinophils in lung. (E) Cytokines measured by ex-vivo recall assays 
with OVA protein (10 μg/mL) in isolated lung cells. Data are expressed as mean ± standard deviation. Means were compared using 1-way analysis of variance 
followed by Tukey’s multiple comparison test when data were normally distributed. 
PBS, phosphate-buffered saline; OVA, ovalbumin; BMDC, bone marrow-derived dendritic cell; OVA-BMDC, ovalbumin-loaded bone marrow-derived dendritic 
cell; Dexa, dexamethasone; Veh, vehicle; i.p., intraperitoneal; i.n., intranasal; i.v., intravenous; H&E, hematoxylin and eosin; PAS, periodic acid–Schiff; IL, 
interleukin; ELISA, enzyme-linked immunosorbent assay; NS, not significant; OD, optical density; IgE, immunoglobulin E. 
*P < 0.05, †P < 0.01, ‡P < 0.001.
These results suggested i.v. OVA-BMDC-transferred asthma model mice are partially resistant 
to steroid treatment, similar to that in severe human asthma.
DISCUSSION
In the present study, we successfully developed a murine asthma model by i.v. transfer of OVA-
BMDCs. The model showed typical histological (Fig. 2) and immunological alterations (Figs. 3 
and 4) representing heterogeneous human-like asthma, with low variability among individual 
animals (Figs. 2C and 3B). In addition, this model was partially resistant to steroid treatment, 
a characteristic of severe human asthma (Fig. 5). To induce robust systemic immune 
responses, we used antigen-presenting DCs, which are pivotal in T-cell differentiation and in 
the initiation and maintenance of allergic responses. The allergen OVA was directly transferred 
into the mice with the DCs, resulting in a more severe asthma phenotype.
Several previous murine models of asthma relied on the transfer of DCs. For example, OVA-
loaded splenic DCs were administered i.p. once for sensitization.30 However, the number of 
spleen cells available was insufficient to generate multiple murine models simultaneously. 
Therefore, studies have used BMDCs cultured for 6 to 8 days in medium containing GM-CSF. 
For example, OVA-BMDCs have been administered i.n.31,32 or i.t.33,34 to mice for sensitization. 
However, mice were anesthetized for OVA-BMDC administration in these studies. 
Furthermore, all of these previous models using DCs require repeated secondary i.n. or 
aerosol OVA challenge and thus, were not advantageous compared to conventional methods.
Our new asthma model provides significant research advantages compared to current models. 
First, our model better mimics heterogeneous human asthma, with a boosted immune 
response. In human asthma, Th2-mediated eosinophilic inflammation is the most common 
endotype, but Th1 and Th17 cells are also involved in the pathogenesis and are related with 
the heterogeneous features of asthma.4,5,24,35 Raundhal et al.36 reported increased expression of 
IFN-γ+ CD4 (Th1) cells in patients with severe asthma. Th17 cells, which mediate neutrophil 
recruitment, are associated with resistance to steroid therapy and severe clinical course of 
asthma.37 Consequently, neutrophil infiltration is related with a severe disease phenotype in 
humans3,38 and mice.39 Patients with severe or steroid-resistant asthma show Th2 mixed with 
Th17 or Th1 immune responses.40,41 Our model showed elevated Th17 immune responses as 
well as a Th2 response, including eosinophil and neutrophil infiltration, and was partially 
resistant to steroid treatment, thus being a good model of human asthma.
Secondly, this DCs-based asthma model could be useful for immunologic studies on the 
functions of DCs and T-cell responses in asthma. For example, manipulation of DCs in vitro, 
such as treatment with specific cytokines or adjuvants, followed by in vivo administration 
might aid in investigating the role of different pathways in DCs and elucidating the disease 
mechanism.31 Furthermore, in vivo transfer of allergen-loaded DCs is useful for investigating 
the pathogenesis of asthma while conserving the experimental animals. For example, DCs 
isolated from type I IFN receptor-deficient mice, which cannot initiate Th2 responses42 or 
from IL-33 knockout mice, which have alleviated asthma features,43 could be applied for 
immunological studies.
Thirdly, the degree of asthma inflammation can be controlled by varying the number of cells 
injected. More severe asthma could be established by increasing the cell number; 1 × 107 cells 
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induced the most severe lung inflammation and goblet cell hyperplasia in the present study. 
This demonstrated that disease severity and asthma type can be adjusted to the research aims.
Fourthly, notably, asthma can be induced with less variation among individuals. In our data, 
inflammatory and PAS scores of lung histology (Fig. 2C) as well as serum OVA-specific IgE 
levels (Fig. 3B) were more constant in i.v. OVA-BMDC-transferred asthma model mice than 
in conventional asthma model mice. This advantage is in contrast to the risk of aspiration or 
ejection of allergen in conventional i.n. challenge. Fifthly, using BMDCs instead of splenic 
DCs shows high productivity and good economic efficiency. From 1 mouse, sufficient BMDCs 
can be harvested to generate 100 asthma model mice; thus, BMDCs are more economical 
than splenic DCs. Sixth, mice need not to be anesthetized, which reduces stress in the 
animals and researchers. Finally, the administration of allergen-loaded materials (OVA-
BMDCs) takes less time than conventional methods.
Interestingly, i.v. injection of OVA-BMDCs alone 3 times, without i.p. OVA sensitization, 
over 5 days elicited an asthma phenotype comparable to that induced by conventional 
5 times i.n. administration of OVA over 26 days, although serum IgE and IgG were not 
elevated. Therefore, i.p. sensitization is required for antigen-antibody immune responses. 
In summary, i.p. OVA sensitization combined with i.v. OVA-BMDC transfer can be used to 
establish an ideal model of asthma in mice. The characteristics of the different protocols used 
to establish asthma murine models are described in Table.
In the present study, we used the i.v. route (via the tail vein) to develop asthma, which can be 
inconsistent with the pathophysiology of asthma. However, the vast majority of mouse models 
rely on systemic sensitization of the immune system, although the site of allergen sensitization 
in humans is the airway itself.44 Moreover, Medoff et al.45 and Li et al.46 proved the feasibility 
of the i.v. route to induce allergic airway inflammation using T-cell transfer. According to 
Eggert et al.,47 i.v. injected BMDCs mainly accumulated in capillary-rich, well-perfused organs, 
such as the lungs and spleen, and MLNs. Komaru et al.48 applied i.v. administration of virally 
activated BMDCs to inhibit lung metastasis in a murine tumor model. The DCs administered 
via the tail vein migrated to the peritoneal vein and systemically circulated, and then entered 
the pulmonary vein and capillary and finally, the bronchial lumen by extravasation. The 
systemic immune response was directly driven by antigen-presenting DCs. The populations 
of inflammatory and goblet cells expanded in proportion to the number of OVA-BMDCs 
injected. Immunological parameters, including serum OVA-specific IgE, cytokines, and T-cell 
transcription factors supported good establishment of asthma. In this study, we aimed to 
develop a murine model of asthma with a stronger immune response using DCs. Furthermore, 
this DCs-based asthma model could be useful for immunological studies on the functions of 
DCs and T-cell responses in asthma. By controlling the characteristics and number of DCs, the 
T-cell immune response can be adjusted.
This study also has some limitations. First, an additional procedure for preparing allergen-
loaded DCs is required. BMDCs were generated and cultured for 9 days; this in vitro procedure 
requires technical proficiency and is quite costly. Secondly, OVA is not physiologically relevant 
in humans. Nevertheless, this study provided proof of concept for i.v. transfer of OVA-BMDCs, 
and further studies are needed to investigate the asthma model using other allergens, such 
as house dust mite. Thirdly, our model shows enhanced systemic inflammation besides local 
airway inflammation. However, considering that this is a murine model that mimics human 
asthma and that mice do not develop human-like asthma naturally, systemic sensitization via an 
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i.p. route is generally required to boost immune responses in order to generate asthma in mice. 
This could elicit systemic inflammation, although sensitization in humans is highly unlikely 
to occur through the peritoneum. This could be an inevitable characteristic and limitation of 
the currently available murine models. In the present study, although we have not evaluated GI 
tract or heart, other organs might also be affected by i.v. transfer of OVA-BMDCs. The enhanced 
systemic immune response is a special characteristic and could be an advantage of the present 
model because individuals with asthma sometimes exhibit features of systemic allergy with 
local allergy response. Moreover, systemic immune response could reflect local airway 
inflammation such as severity of asthma. For example, the serum level of allergen-specific IgE is 
a parameter of inflammation in asthmatic patients as well as asthmatic mice. Finally, this study 
does not clarify the detailed mechanism of Th2/Th17 induction by OVA-BMDCs in depth, since 
we focused mainly on generation of the model of asthma in this study. We are planning further 
studies to investigate the detailed mechanism of Th2/Th17 induction by OVA-BMDCs and the 
effect of other adjuvants in the asthma model.
550https://e-aair.org https://doi.org/10.4168/aair.2020.12.3.537
Asthma Model With Th2/Th17-Skewed Response
Table. Comparison of several methods to induce asthma in mice
Methods Technical and experimental aspects Immunological and pathophysiological aspects References
i.p. allergen + 
i.n. allergen
Advantage Advantages 12-14
• Most traditional and conventional method • Physiologic route of allergen inhalation
• Th2 dominant immune response
• Eosinophil infiltration
• More goblet cell hyperplasia than aerosol challenge method
Disadvantages Disadvantages
•  Requirement of anesthesia (stressful for both mice and the 
researcher, permission required, and handle with care)
• Possibility of nasal allergic inflammation by allergen exposure
• Lack of asthma phenotype of Th17 and neutrophilic responses
• Risk of aspiration
• Need of many allergen challenging
• Variation between individuals
i.p. allergen +  
i.t. allergen
Advantage Advantages 15-17
• Low allergen dose required • Physiologic route of allergen inhalation directly to lung
• Th2 dominant immune response
• Eosinophil infiltration
Disadvantages Disadvantage
•  Invasive method (risky and stressful for both mice and 
researcher)
• Lack of asthma phenotype of Th17 and neutrophilic responses
•  Requirement of anesthesia (stressful for both mice and 
researcher, permission required, and handle with care)
• Requirement of multiple allergen challenges
i.p. allergen + 
aerosol allergen
Advantage Advantages 13,18,19
•  No need for anesthesia (less stressful for both mice and 
researcher)
• Physiologic route of allergen inhalation
• Th2 dominant immune response
• Eosinophil infiltration
• More mast cell infiltration than i.n. challenge method
Disadvantages Disadvantages
• Requirement of high allergen dose • Possibility of skin allergic inflammation by allergen exposure
• Requirement of considerable time in aerosol chamber • Lack of asthma phenotype of Th17 and neutrophilic responses
• High cost of aerosol chamber
i.p. allergen +  
i.v. allergen-
loaded BMDCs
Advantages Advantages In this study
• Low variability between individuals • Robust systemic immune response (serum IgE and IgG1)
•  No need for anesthesia (less stressful for both mice and 
researcher)
•  Stronger Th2/Th17 immune response induction in a short 
period
• Short time for allergen challenging • Eosinophil/neutrophil infiltration
• High productivity (good economic efficiency) •  Generation of more severe asthma by increasing the 
number of BMDCs
Disadvantage Disadvantage
• Effort for preparation of allergen-loaded BMDCs •  Possibility of nasal and skin allergic inflammation by 
allergen exposure
i.p., intraperitoneal; i.n., intranasal; i.t., intratracheal; BMDCs, bone marrow-derived dendritic cells; Th, T-helper; Ig, immunoglobulin.
Despite these limitations, the present study provided significant research advantages in that it 
established a reliable asthma model with low variation between individuals. Immune responses 
could be induced without anesthesia, and the degree of asthma inflammation can be controlled 
by varying the number of cells injected. Our model showed elevated Th17 immune responses 
as well as a Th2 response, including eosinophil and neutrophil infiltration, and was partially 
resistant to steroid administration. This is important because patients with severe or steroid-
resistant asthma show mixed Th1/Th2/Th17 immune responses, and because neutrophil 
infiltration is related to a severe disease phenotype. Most of the murine asthma models 
developed to date show an allergic/eosinophilic phenotype, but lack a non-allergic/neutrophilic 
phenotype.21 Although a murine model of neutrophilic asthma was recently reported,49 it did 
not reflect heterogeneous asthma showing mixed eosinophilic/neutrophilic inflammation. 
Thus, the present model more accurately reflects the clinical features of heterogeneous human 
asthma and might offer an excellent experimental platform for the development of therapeutic 
strategies. Furthermore, this DCs-based asthma model can be used in further studies evaluating 
the effects of specific DC subsets or certain allergen-loaded DCs on asthma induction.
In conclusion, we developed a reliable and reproducible murine model of asthma for the first time 
using i.v. transfer of OVA-BMDCs. This model well mimicked heterogeneous human asthma. 
More severe asthma could be induced by increasing the number of cells transferred, and this 
model can be produced on a relatively large scale. Importantly, the good reproducibility, with low 
variation among individuals, and the fact that it does not require anesthesia support its usefulness 
for future studies on asthma. We expect that this i.v. OVA-BMDC-transfer murine model of asthma 
will contribute to the elucidation of the pathophysiology of this heterogeneous disease as well as 
to the identification of novel molecular targets for anti-inflammatory therapies for asthma.
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SUPPLEMENTARY MATERIALS
Supplementary Fig. S1
Lung histology and serum OVA-specific Ig in control and asthma groups. (A) Representative 
H&E-stained lung tissue sections (original magnification: 100×, magnified image of the 10× 
image in the left upper quadrant, scale bar: 100 μm). (B) Representative PAS-stained sections 
(original magnification: 200×, scale bar: 50 μm). (C) Lung inflammation and PAS-positive 
cell score. (D) Serum OVA-specific Ig measured by ELISA. Figures comprise histological 
examination data representative of 5 to 7 mice per group. All data are representative of 3 
independent experiments with similar results. Data are expressed as the mean ± standard 
deviation. Means were compared using one-way analysis of variance followed by Tukey's 
multiple comparison test when data were normally distributed.
Click here to view
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Supplementary Fig. S2
Analysis of lung histology upon transfer of different numbers of OVA-BMDCs in i.v. OVA-
BMDC-transferred asthma model mice. (A) Representative H&E-stained lung tissue sections 
(original magnification: 100×, magnified image of the 10× image in the left upper quadrant, 
scale bar: 100 μm). (B) Representative PAS-stained sections (original magnification: 
200×, scale bar: 50 μm). (C) Lung inflammation and PAS-positive cell score. Figures 
comprise histological examination data representative of 5 to 7 mice per group. All data 
are representative of 3 independent experiments with similar results. Data are expressed as 
the mean ± standard deviation. Means were compared using one-way analysis of variance 
followed by Tukey's multiple comparison test when data were normally distributed.
Click here to view
Supplementary Fig. S3
Characterization of injected OVA-BMDCs by flow cytometry. (A) CD11c+ MHC II+ DCs were 
gated. The expression of CD80, CD86 and OX40 ligand was measured by flow cytometry. 
(B) Gating strategy for OVA-BMDCs generated using different concentrations of OVA. (C) 
The expression of CD80 and CD86 increased as the concentration of OVA increased. The 
expression of OX40 ligand also increased as the OVA concentration increased, and peaked 
at 500 μg/mL. All data are representative of 3 independent experiments with similar results. 
Data are expressed as the mean ± standard deviation. Means were compared using one-way 
analysis of variance followed by Tukey's multiple comparison test when data were normally 
distributed. OVA, ovalbumin; BMDC, bone marrow-derived dendritic cell; OVA-BMDC, 
ovalbumin-loaded bone marrow-derived dendritic cell; DC, dendritic cell; MFI, mean 
fluorescence intensity.
Click here to view
Supplementary Fig. S4
Analysis of cytokine levels in spleen and MLN cells. Cytokines were measured by ex-vivo recall 
assays with OVA protein (10 μg/mL) in isolated spleen cells (A) and MLN cells (B). All data 
are representative of 3 independent experiments with similar results. Data are expressed 
as means ± standard deviation. Means were compared using one-way analysis of variance 
followed by Tukey's multiple comparison test when data were normally distributed.
Click here to view
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